Incannex Healthcare Inc. (IXHL)
Incannex Healthcare Inc. (IXHL) Stock Price, Analysis & Data
| Bid | 2.27 |
| Market Cap | 37.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -48.41M |
| Beta | 2.81 |
| EPS (ttm) | -16.62 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.87 |
| P/B (ttm) | 0.58 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 4.01 |
| Volume | 73,670 |
| Avg. Volume (20D) | 221,798 |
| Open | 3.16 |
| Previous Close | 3.20 |
| Day's Range | 3.09 - 3.21 |
| 52-Week Range | 2.49 - 27.69 |
| Analyst | n/a |
| Price Target | 17.95 (466.25%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IXHL
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical deve...
Financial Performance
In 2024, Incannex Healthcare's revenue was 12K, an increase of undefined% compared to the previous year's 0. Earnings were -18.46M, a decrease of -62.18%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for IXHL stock is "null". The 12-month stock price forecast is 17.95, which is upside of 466.25% from the latest price.
Stock Forecasts
